Cancer Stem Cell News Volume 11.07 | Feb 23 2022


    2022-02-23 | CSCN 11.07

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 11.07 – 23 February, 2022

    USP33 Deubiquitinates and Stabilizes HIF-2alpha to Promote Hypoxia Response in Glioma Stem Cells

    Researchers identified USP33 as essential deubiquitinase that stabilized HIF-2alpha protein in an ERK1/2-dependent manner to promote hypoxia response in cancer cells.
    [EMBO Journal]

    AbstractGraphical Abstract

    Register now for the 5th DNA Repair/Replication Structures and Cancer Conference.
    PUBLICATIONSRanked by the impact factor of the journal

    METTL3 Promotes Oxaliplatin Resistance of Gastric Cancer CD133+ Stem Cells by Promoting PARP1 mRNA Stability

    The in vitro and in vivo results indicated that CD133+ stem cell-like cells were the main subpopulation and PARP1 was the central gene mediating oxaliplatin resistance in gastric cancer.
    [Cellular and Molecular Life Sciences]


    Wasl Is Crucial to Maintain Microglial Core Activities during Glioblastoma Initiation Stages

    Scientists showed that microglial morphology and functions were already impaired during glioma initiation stages.

    Full Article

    FAM83A Is a Potential Biomarker for Breast Cancer Initiation

    Biological and molecular alterations upon family with sequence similarity 83 member A (FAM83A) overexpression/downregulation and FAM83A’s interaction partners were investigated.
    [Biomarker Research]

    Full Article

    Steroidal Saponins from Trillium tschonoskii Rhizome Repress Cancer Stemness and Proliferation of Intrahepatic Cholangiocarcinoma

    All isolated analogues were screened for the cytotoxicity against intrahepatic cholangiocarcinoma cell lines of HuCCT1 and RBE through tumor colony formation and CCK-8 survival analysis.
    [Bioorganic Chemistry]

    AbstractGraphical Abstract

    Enhanced O-GlcNAc Modification Induced by the RAS/MAPK/CDK1 Pathway Is Required for SOX2 Protein Expression and Generation of Cancer Stem Cells

    Gene knockout studies revealed that SOX2 was an essential factor for the generation of CSCs by HRASV12 in mouse and human fibroblasts.
    [Scientific Reports]

    Full Article

    The Significance of ErbB2/3 in the Conversion of Induced Pluripotent Stem Cells into Cancer Stem Cells

    Scientists established a novel method to generate CSCs from iPSCs under a cancerous microenvironment mimicked by the conditioned medium of cancer-derived cells.
    [Scientific Reports]

    Full Article

    Multiple Transcriptome Analysis of Piwil2-Induced Cancer Stem Cells, including piRNAs, mRNAs and miRNAs Reveals the Mechanism of Tumorigenesis and Development

    Researchers sequenced the piRNAs, miRNAs and mRNAs of Piwil2-iCSCs and fibroblasts, and analyzed the differences.
    [Molecular Biology Reports]


    Telomere Shortening Accelerates Tumor Initiation in the L2-IL1B Mouse Model of Barrett Esophagus and Emerges as a Possible Biomarker

    Scientists investigated the impact of shortened telomeres in a mouse model for Barrett esophagus (L2-IL1B). The L2-IL1B mouse model was characterized by IL-1β-mediated inflammation, which led to a Barrett-like metaplasia in the transition zone between the squamous forestomach and glandular cardia/stomach.

    Full Article

    Activate, expand, and differentiate your cells with cytokines, chemokines, and growth factors from STEMCELL Technologies.

    CRISPR in Cancer Biology and Therapy

    The authors review the progress made in the development of CRISPR systems as a tool to study cancer, and the emerging adaptation of these technologies to improve diagnosis and treatment.
    [Nature Reviews Cancer]

    Full Article

    Targeting Cancer Stem Cells with Antibiotics Inducing Mitochondrial Dysfunction as an Alternative Anticancer Therapy

    Scientists summarize the major recent works on the use of antibiotics to target tumors via CSC and suggest next steps for developing this approach.
    [Biochemical Pharmacology]

    AbstractGraphical Abstract


    Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase II/III Study of AL102 in Desmoid Tumors

    Ayala Pharmaceuticals, Inc. announced that it has completed patient enrollment in Part A of the Phase II/III RINGSIDE clinical trial evaluating AL102 in desmoid tumors.
    [Ayala Pharmaceuticals, Inc.]

    Press Release


    ISSCR: Understanding Stem Cells and Cellular Processes through Imaging

    6 March, 2022

    > See All Events


    Postdoctoral Associate – Liver Cancer

    Baylor College of Medicine – Houston, Texas, United States

    Researcher – Cancer Biology

    BC Cancer Research Institute – BC Cancer Research Institute

    Postdoctoral Associate – Immunology and Nanomedicine

    Florida International University – Miami, Florida, United States

    Postdoctoral Fellow – Cancer Immune Biomarkers

    Albert Einstein College of Medicine – Bronx, New York, United States

    Postdoctoral Scholar – Tumor Immunology

    Moffit Cancer Center – Tampa Bay, Florida, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter